At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.

At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.

Actinic Keratoses

one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas

ingenol mebutate 0.015%

Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent

dermasil lotion

Icahn School of Medicine at Mount Sinai

Treatment of Actinic Keratoses (AK) on the Face

An Investigator-Initiated Study to Assess the Efficacy and Degree of Irritation of Ingenol Mebutate 0.015% Gel and Dermasil Lotion Versus Ingenol Mebuate 0.015% Alone in the Treatment of Actinic Keratoses (AK) on the Face.

Investigator assessment of the degree of irritation as measured by local skin reactions at day 57 as compared to baseline.

Change in the number of AK lesions at 57 days as compared to baseline to assess AK clearance

euphorbia thymifolia/turse

Treatment of Actinic Keratoses (AK) on the Face

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus